FDA greenlights ViiV’s Tivicay PD for HIV-positive newborns in first month of life
RegulatoryapprovedTivicay PDPositive
AI Analysis
Summary
The FDA approved ViiV Healthcare's Tivicay PD (dolutegravir) for treating HIV-1 in pediatric patients weighing at least 2 kg, including newborns in their first month of life, representing a significant label expansion from its original 2013 approval for adults and adolescents.
Outcome Details
FDA approved Tivicay PD for treating HIV-1 in pediatric patients weighing at least 2 kg, including eligible newborns in first month of life
Importance:8/10
Sentiment:
0.90
FDA approvalpediatric indicationHIV treatmentlabel expansionnewborn patients
Read the original article
Published by Drug Discovery & Development on August 26, 2026 3:58 PM